This segment focuses on the research, development, and clinical evaluation of novel therapeutics for various cancers. Aravive's primary focus is on its lead product candidate, AVB-500, a decoy protein designed to target the GAS6-AXL signaling pathway. Research and development activities include preclinical studies, Phase Ib/II clinical trials for platinum-resistant recurrent ovarian cancer, clear cell renal cell carcinoma, HER negative breast cancer, and other cancers. The company utilizes advanced protein engineering and antibody technologies to develop targeted therapies. The patient impact is aimed at improving outcomes and extending the lives of patients with metastatic disease. Market positioning is based on addressing unmet medical needs in oncology. Future opportunities include expanding the clinical trial program and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to clinical trial protocols. Partnerships with companies like 3D Medicines and WuXi Biologics support the development and commercialization of AVB-500 and other bispecific antibodies.